Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

<p>amino acid sequences of mAbs in this study</p>

保存先:

書誌詳細
第一著者:	Yuncheng Bei (16546095) (author)
その他の著者:	Jian He (16546098) (author), Xuhui Dong (16546101) (author), Yuxin Wang (16546104) (author), Sijie Wang (16546107) (author), Wan Guo (16546110) (author), Chengjie Cai (16546113) (author), Zhiye Xu (16546116) (author), Jia Wei (11469308) (author), Baorui Liu (15134681) (author), Nan Zhang (16546119) (author), Pingping Shen (16546122) (author)
出版事項:	2025
主題:	Cancer Therapeutic Research and Development Methods and Technology Biological Agents & Therapies Antibody-drug conjugates Computational Methods Database resources Drug Targets Cell surface receptor drug targets Preclinical Models Xenograft models
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
著者:: Yuncheng Bei (16546095)
出版事項: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
著者:: Yuncheng Bei (16546095)
出版事項: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
著者:: Sheheryar Kabraji (15050565)
出版事項: (2025)

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
著者:: Amr El Zawily (14851115)
出版事項: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
著者:: Martina S.J. McDermott (15206951)
出版事項: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
著者:: Santiago Duro-Sánchez (14959182)
出版事項: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
著者:: Erwin Tomasich (15052256)
出版事項: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
著者:: Niklas Klümper (15048887)
出版事項: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
著者:: Niklas Klümper (15048887)
出版事項: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_gqgfteon4t9vfu27nkstjblbad